T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Publication/Presentation Date

1-1-2010

Abstract

One of the reasons multiple sclerosis (MS) has been considered a T-cell mediated autoimmune disease is that a similar experimental disease can be induced in certain rodents and primates by immunization with myelin antigens, leading to T-cell-mediated inflammatory demyelination in the CNS. In addition, most if not all pharmacological treatments available for MS are biologically active on T cells. In this article we review the principles of T-cell-based immunotherapies and the specific actions of current and novel treatments on T-cell functions, when these are known. For both licensed and innovative agents, we also discuss biological actions on other immune cell types. Finally, we offer a brief perspective on expected changes in the use of MS immunotherapies in the near future.

Volume

2

Issue

1

First Page

99

Last Page

115

ISSN

1750-7448

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

20231863

Department(s)

Administration and Leadership

Document Type

Article

Share

COinS